27 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 664

JA Solar Debuts Next-Generation n-Type TOPCon Module DeepBlue 5.0

BEIJING, Jan. 30, 2025 /PRNewswire/ — JA Solar, a global leader in the PV industry, proudly launched its latest innovation, the DeepBlue 5.0 PV module in January. With its significant advancements in efficiency, reliability, and adaptability, the DeepBlue 5.0 marks a transformative step forward in PV technology.

Leveraging the advanced Bycium+ 5.0 cell technology, the DeepBlue 5.0 integrates multiple cutting-edge technologies, such as upgraded electrical architecture, optimized material enhancements, and structural refinements. These innovations enable a module power up to 670W and module efficiency up to 24.8%. The module also boasts superior performance in low-light environments and complex weather conditions, ensuring stable energy output across diverse applications.

“At JA Solar, innovation is at the core of our mission to accelerate the global transition to clean energy,” said Aiqing Yang, Executive President of JA Solar. “The DeepBlue 5.0 represents our commitment to delivering products that combine exceptional performance, cost efficiency, and reliability, empowering our customers to achieve their sustainability goals.”

The DeepBlue 5.0 is built on innovative optical absorption and electrical optimization techniques, reducing the Levelized Cost of Energy by up to 4.3% compared to its predecessor, DeepBlue 4.0 Pro. JA Solar has enhanced the module across three critical areas. The wafer offers improved resistivity uniformity, ultra-low oxygen content (3 ppma), and superior minority carrier lifetime. The Bycium+ 5.0 cell features high-efficiency n-type passivated contact technology, optimized light absorption, and an ultra-high open-circuit voltage of 749 mV. The module incorporates innovations such as PII, HDP, UTG, and CSE technologies, ensuring exceptional durability and reliability in extreme conditions. With a first-year degradation rate of ≤1% and annual linear degradation of ≤0.4%, the DeepBlue 5.0 sets a new benchmark for efficiency and performance.

The DeepBlue 5.0 modules are scheduled for mass production in Q4 2025, with initial power ratings ranging from 640W to 670W. Designed to meet the growing demand for high-efficiency modules in premium markets, the DeepBlue 5.0 aims to deliver unparalleled value for utility-scale, commercial, and residential PV projects worldwide.

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

TOKYO, Jan. 30, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2

JPY 670 Million (USD 4.2 Million1) Investment in a Critical Diagnostic Tool to Combat Leishmaniasis
There is an estimated 700,000 to 1 million new cases annually of leishmaniasis, an NTD caused by Leishmania parasites transmitted through sandfly bites.3 To advance measures against the disease, the GHIT Fund has decided to invest JPY 670 Million (USD 4.2 Million1) to support a project led by the Ohio State University in collaboration with Nagasaki University and icddr,b, an international health research organization based in Bangladesh. Building on previous research, the project will refine formulations of the leishmanin antigen, conduct pre-clinical safety and efficacy studies, and prepare for regulatory submissions for clinical trials. This project aims to strengthen efforts to monitor infection status and eliminate visceral leishmaniasis. The initiative, driven by global partnerships, is expected to make a significant contribution to tackling NTDs and advancing global health.

The GHIT Fund will also invest in two malaria projects: approximately JPY 680 million (USD 4.2 million1) for the development of a malaria therapeutic drug through a partnership between Eisai Co., Ltd. (Eisai) and Medicines for Malaria Venture (MMV) and approximately JPY 585 million (USD 3.7 million1) for the development of a preventive drug for P. falciparum malaria under the partnership of Program for Appropriate Technology in Health (PATH), GSK Global Health, Eisai and Ehime University.

In addition, the GHIT Fund will invest in the following five screening projects for a total amount of approximately JPY 83 million (USD 0.5 million1):
1) Screening project against malaria by MMV and Daiichi Sankyo Co., Ltd.
2) Screening project against dengue and Zika by Eisai and Drugs for Neglected Diseases initiative (DNDi)
3) Screening project against Lassa fever by MMV and RIKEN
4) Screening project against Rift Valley fever by MMV and RIKEN
5) Screening project against Ebola and Marburg by MMV and RIKEN

Please refer to Appendix 1 for detailed descriptions of these projects and their development stages.

As of January 30, 2025, the GHIT Fund has invested in 37 projects, including 15 discovery projects, 14 preclinical projects and eight clinical trials.4 The total amount of investments since 2013 is JPY 35.8 billion (USD 226 million1) (Appendix 2).

1 USD1 = JPY158.15, the approximate exchange rate on December 30, 2024.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002 and RFP2024-001 for the Product Development Platform and the Screening Platform, which were open for applications from June 2023 to July 2024.
3 WHO: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
4 This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en

Appendix 1. Project Details

ID: G2023-202

Project Title

Production and pre-clinical testing of cGMP grade Leishmania donovani antigen for Leishmanin skin test (LST)

Collaboration
Partners

  1. The Ohio State University (USA)
  2. Institute of Tropical Medicine at Nagasaki University (NUITM) (Japan)
  3. icddr,b (Bangladesh)

Disease

Leishmaniasis

Intervention

Diagnostics

Stage

Pre-clinical

Awarded Amount

JPY 670,108,468 (USD 4.2 million)

Status

Continued project

Summary

[Project objective] The objectives of this continuation proposal are to: 1. Produce and characterize cGMP-grade Leishmania antigen (liquid or lyophilized) from L. donovani. 2. Test cGMP leishmanin antigen formulations (liquid and lyophilized) by performing LST in animal models. 3. Perform pre-clinical toxicology studies with cGMP leishmanin antigen formulation that is selected for further advancement based on results from LST studies in animals. 4. Analyze cytokine production in PBMCs or whole blood isolated from healthy individuals and cured VL patients following in vitro stimulation with the selected formulation of cGMP leishmanin antigen. 5. Prepare an IND package for clinical trials. 

[Project design] During the previous funding period, the project team successfully accomplished goals of the project by 1) optimizing the protocol to produce and scale up production of leishmanin antigen from L. donovani parasites using a cost-effective, scalable and industry suitable osmotic shocklysis technique; 2) performed stability studies; 3) validated GLP leishmanin antigen using experimental animal models, and 4) completed manufacturing of cGMP cell bank of L. donovani at ATCC. In this project, three different formulations of leishmanin antigen will be produced from cGMP L. donovani cell bank. The formulations will be validated for safety and potency using preclinical animal models of vaccination and cured VL. One formulation will be selected for further advancement and scale-up of cGMP production on the basis of results from stability studies and LST studies in animals, and pre-clinical toxicology studies will be performed as per regulatory guidelines. To assess the immunogenicity of the product, cytokine production in PBMCs or whole blood isolated from healthy individuals and cured VL patients following in vitro stimulation with the selected formulation of cGMP leishmanin antigen will also be analyzed. IND package will be prepared for submission to regulators for clinical trials.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/226/en

ID: G2024-114

Project Title

Lead optimization and preclinical studies of new antimalarial Gwt1p-inhibitors with a novel mechanism of action, improved efficacies and safety profiles

Collaboration
Partners

  1. Eisai Co., Ltd. (Eisai) (Japan)
  2. Medicines for Malaria Venture (MMV) (Switzerland)

Disease

Malaria

Intervention

Drug

Stage

Lead Optimization

Awarded Amount

JPY 680,010,000 (USD 4.3 million)

Status

Continued project

Summary

[Project objective]

The objective of this proposal is to investigate the new Gwt1p-inhibitor and find a back-up candidate with improved activity and safety profile. To deliver this goal, the project team will focus on the following specific objectives:

(1) Two chemical series will be chemically optimized and a frontrunner compound will be selected from each series, as precandidates.

(2) Two precandidates will be evaluated in multiple assays and the most favorable compound will be selected as a Late Lead.

(3) The synthetic route of Late Lead will be optimized and GLP manufacturing will be conducted.

(4) Non-rodent DRF study will be conducted and candidate selection will be scheduled following a successful outcome to this study.

[Project design] In this project, chemical modification of two lead series will be conducted to improve anti-Plasmodium activity and safety profile while securing a long-half-life. Synthesized new compounds will be shipped to Eisai’s Tsukuba Research Laboratories in Japan. They will be tested according to the defined screening cascade starting from the primary screening of anti-Plasmodium activity and cytotoxicity. Compounds which show good anti-Plasmodium activity and safety margin will be tested for solubility at neutral pH and stability against human and murine liver microsomes assays. Based on these results and other profiling, the most promising compound in each series will be selected as pre-candidate and will be further evaluated. Two precandidates will be evaluated in the in vitro/vivo anti-Plasmodium assay, a rat dose range finding (DRF) study, safety profiling, human dose prediction, salt selection, resistant risk assessment and parasite life-cycle assays. The most favorable compound will be selected as a Late Lead. The synthetic route for the Late Lead will be optimized and GLP manufacturing will be conducted. Non-rodent DRF study using the manufactured GLP material will also be conducted. The final goal of this project is the candidate selection in both Eisai and MMV and planned for September 2026.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/227/en

ID: G2023-219

Project Title

Manufacture of clinical trial material for a monoclonal antibody to prevent P. falciparum malaria

Collaboration
Partners

  1. Program for Appropriate Technology in Health (PATH) (USA)
  2. GlaxoSmithKline Investigacion y Desarrollo, S.L. (Spain)
  3. Eisai Co., Ltd. (Eisai) (Japan)
  4. Ehime University (Japan)

Disease

Malaria

Intervention

Drug

Stage

Pre-clinical

Awarded Amount

JPY 585,190,112 (USD 3.7 million)

Status

Continued project

Summary

[Project objective]

The objective of this project is to complete GMP drug substance and GMP drug product manufacturing to support the future Investigational New Drug Application (IND) submission to the United States Food and Drug Administration (US FDA) for a proof-of-concept clinical trial that includes controlled human malaria infection. Our long-term goal is to secure a WHO recommendation for a mAb that prevents P. falciparum malaria in young children living in areas of seasonal transmission in sub-Saharan Africa.

[Project design] The project is built on our successful completion of the following activities: 1) production and release of a pre-master cell bank for the candidate mAb; 2) development and optimization of the manufacturing process for the candidate mAb to confirm production conditions for Good Laboratory Practice toxicology studies and future scale-up; 3) formulation development to enable stability of the mAb at a high concentration to accommodate potential subcutaneous injection; and 4) a pre-IND meeting with the US FDA on the proposed nonclinical and clinical program, specifically on the adequacy of the nonclinical toxicology studies to support the FIH Phase 1 study.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/228/en

ID: S2024-111

Project Title

Hit Validation of novel Daiichi Sankyo compounds with antimalarial activity

Collaboration
Partners

  1. Medicines for Malaria Venture (MMV) (Switzerland)
  2. Daiichi Sankyo Co., Ltd. (Japan)

Disease

Malaria

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 4,000,000 (USD 25,292.44)

Status

Continued project

Summary

[Project objective]

The objective of the Hit Validation project is the synthesis and testing of a small array of compounds designed to investigate the minimum pharmacophore, key structural features required for activity and scope to address issues identified through the profiling of the hits identified from the earlier HTS campaign (S2020-113). If a compelling data package is obtained and the series clear potential for further development towards an Early Lead, a GHIT HTLP proposal will be submitted.

[Project design] The focus of the array of analogs is to explore the key features required for activity and scope to address potential issues. A feature of the overall design of the array is focused on modifications with potential to improve the metabolic stability of the series in line with potential to deliver a long duration antimalarial (predicted human T1/2 > 120 h). The lipophilicity of the analogues covers a range of values from approximately 1.5 to 4.5 which will help to identify if data (potency, metabolism, cytotoxicity, etc.) correlates with either LogP or LogD.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/229/en

ID: S2024-123

Project Title

Exploration of Novel Antiviral Compounds for the Development of Therapeutics Against Flavivirus Infections

Collaboration
Partners

  1. Eisai Co., Ltd. (Eisai) (Japan)
  2. Drugs for Neglected Diseases initiative (DNDi) (Switzerland)

Disease

Dengue and Zika

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 12,653,193 (USD 80,007.54)

Status

New

Summary

[Project objective]

The project team aims to identify hit compounds that will serve as the starting point for new drug development by exploring novel compounds that exhibit antiviral activity against flaviviruses such as dengue virus and Zika virus.

[Project design] To explore compounds that exhibit antiviral activity against dengue virus and Zika virus, the project team will screen two types of compound libraries, a focused library and a diversity library, using an image-based phenotypic assay system. In the phenotypic assay system, viral proteins and host cell nuclei are stained, and the antiviral activity of the compounds is determined by analyzing fluorescent confocal images. The focused library consists of compounds selected by a machine learning model developed using assay data accumulated by Eisai. By complementarily utilizing the diversity library, the project team efficiently explores compounds that exhibit antiviral activity. Ultimately, the project team aims to identify hit compounds that show activity against dengue virus and Zika virus to establish preliminary structure-activity relationships, physicochemical properties, and other relevant biological information.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/231/en

ID: S2024-113

Project Title

Screening Project between RIKEN and MMV

Collaboration
Partners

  1. Medicines for Malaria Venture (MMV) (Switzerland)
  2. RIKEN (Japan)

Disease

Lassa Fever

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 20,064,000 (USD 126,866.90)

Status

New

Summary

[Project objective]

The project aims to use a cell-based, infection-free platform to identify potential treatments against LASV using the RIKEN NPDepo library. Additionally, the project seeks to study the effectiveness of selected confirmed treatments against lymphocytic choriomeningitis virus (LCMV), Tacaribe virus (TCRV), and Junin virus (JUNV) in order to identify potential broad-spectrum antiviral compounds. This collaboration leverages the screening capabilities and drug development expertise of Japan’s largest comprehensive institution, PDP, and academic investigators to achieve its goals.

[Project design] The primary screen will use LASV-vRNP/293mRFP to assess a subset of the RIKEN NPDepo library. The screen will be in a 384-well plate format with a single compound concentration of 10 µM. Compounds will be evaluated for their antiviral activity and impact on cell viability. Approximately 200 compounds will be selected for further confirmation studies based on specific criteria. Confirmed actives will undergo broad-spectrum antiviral testing and prioritization for further profiling. Selected hits meeting specific criteria will be considered for future development.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/232/en

ID: S2024-114

Project Title

Screening Project between RIKEN and MMV

Collaboration
Partners

  1. Medicines for Malaria Venture (MMV) (Switzerland)
  2. RIKEN (Japan)

Disease

Rift Valley fever

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 23,712,000 (USD 149,933.61)

Status

New

Summary

[Project objective]

The project aims to use a live virus platform to identify potential compounds active against the Rift Valley fever virus (RVFV) using the RIKEN NPDepo library. Furthermore, the project intends to investigate the activity of selected compounds against the Punta Toro virus and La Crosse virus in order to identify potential broad-spectrum anti-bunyavirus compounds. This collaboration leverages the screening capabilities and drug development expertise of Japan’s largest comprehensive research institution, PDP, and academic investigators to achieve its goals.

[Project design] The initial screening will involve using the MP-12 strain of RVFV to infect human hepatocyte cells. A subset of the RIKEN NPDepo library (20,000 compounds) will be screened in a 384-well plate with a single compound concentration of 10 µM. The results will be evaluated for antiviral activity and cell viability, and potential hits will be chosen based on specific criteria.

About 100 compounds (assuming a 0.5% hit rate) will be selected from the screening for further confirmation studies. These studies will involve testing the compounds at three different doses in cultured cells infected with RVFV, similar to the initial screen, and assessing cytotoxicity. From the confirmed compounds, RIKEN and MMV will prioritize up to 5 hits for further evaluation.

To assess the potential for broad-spectrum anti-bunyaviral activity, the confirmed compounds will be tested against Punta Toro virus and the more distantly related La Crosse virus.

The hit series meeting MMV and GHIT criteria for further development (hits with confirmed EC50 < 5 µM against live viruses and a selectivity index (SI = CC50/EC50) of ≥10, with progressable chemotypes) will form the basis of a future GHIT HTLP application. 

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/233/en

ID: S2024-115

Project Title

Screening Project between RIKEN and MMV

Collaboration
Partners

  1. Medicines for Malaria Venture (MMV) (Switzerland)
  2. RIKEN (Japan)

Disease

Ebola and Marburg

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 22,800,000 (USD 144,166.93)

Status

New

Summary

[Project objective]

The project aims to use a multi-filovirus “rainbow” system that can simultaneously test for EBOV, MARV, and SUDV using a single cell line to identify potential treatments against filoviruses using the RIKEN NPDepo library. Additionally, the project seeks to study the effectiveness of selected confirmed hits against other filoviruses (Tai Forest, Reston, Bundibogyo, Lloviu) in order to identify potential broad-spectrum antiviral compounds. This collaboration leverages the screening capabilities and drug development expertise of Japan’s largest comprehensive institution, PDP, and academic investigators to achieve its goals.

[Project design] The primary screen will be performed on a subset of the RIKEN NPDepo library (20,000 compounds). The screen will be in a 384-well plate format with a single compound concentration of 10 µM. Compounds will be evaluated for their antiviral activity and impact on cell viability. Approximately 200 compounds will be selected for further confirmation studies based on specific criteria. Confirmed actives will undergo broad-spectrum antiviral testing and prioritization for further profiling against live Ebola virus. Selected hits meeting specific criteria will be considered for future development.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/234/en

*All amounts are listed at an exchange rate of USD1 = JPY158.15, the approximate exchange rate on December 30, 2024.

Appendix 2. Investment Overview (as of January 30, 2025)

Investments to date
Total investments: 35.8 billion yen (USD 226 million1)
Total invested projects: 133 (37 active projects and 96 completed projects)
To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

For more information, contact:
Katy Lenard at +1-202-494-2584 or klenard@burness.com
Mina Ohata at +81-36441-2032 or mina.ohata@ghitfund.org

SMMT – Vehicle production dips amid EV transformation and intense market pressure

  • British vehicle production slips -11.8% to 905,233 units in 2024, with cars down to 779,584, as industry continues transformation to EV production.
  • 4.0% growth in commercial vehicle production fails to offset -13.9% decline in car output.
  • Potential to surpass one million cars and light vans in 2028 if markets improve and model launches stay on track.
  • Sector calls for government to fast track industrial and trade strategies for automotive manufacturing.

LONDON, Jan. 30, 2025 /PRNewswire/ — UK vehicle production dipped below one million units in 2024, according to the latest figures published today by the Society of Motor Manufacturers and Traders (SMMT). Factories turned out 779,584 cars and 125,649 commercial vehicles (CVs), a total of 905,233 units and -11.8% lower than in 2023. While CV output grew by 4.0%, its best level since 2008, multiple factors impacted car volumes, with the end of production for some long running models as factories retooled for EVs, weakness in key global markets, and a slowdown in the transition to electrification amid tough economic conditions.

 

Top UK Car Exports 2024
Top UK Car Exports 2024

 

Following a slew of restructuring announcements across the UK and Europe, reflecting the challenges of moving from ICE to EV production, December rounded off 10 consecutive months of decline for British car production, with output down -27.1% to 45,022 units. Over the year, car production fell -13.9%, with output for the UK market down by -8.0% to 176,019 units, while exports declined -15.5% to 603,565 units.

Nearly eight-in-10 cars produced were destined for export last year, with 77.5% (467,937 units) shipped to the top three markets: the EU (54.0%), US (16.9%) and China (6.6%). Exports to the EU and China were down -24.3% and -21.8% respectively, but those to the US rose 38.5%, emphasising the need for supportive trading conditions across the Atlantic. Turkey and Japan rounded off the UK’s top five global export markets, followed by Australia, Canada, South Korea, UAE and Israel.

Given the wholesale transformation underway at many car factories, a decline in battery electric (BEV), plug-in hybrid (PHEV) and hybrid (HEV) vehicle output was expected. Volumes of these electrified technologies fell to 275,896 units, down -20.4% on the year before but still accounted for 35.4% of overall output and the second highest on record. With more than £20 billion worth of investment announced in 2023 and a further £3.5 billion in 2024 to drive the UK’s transition to EV production, the decline will be temporary.1

Mike Hawes, SMMT Chief Executive, said, “Amid significant geopolitical and trade tensions, UK manufacturers are set on turning billions of pounds of investment into production reality, transforming factories to make new electric vehicles for sale around the world. Growing pains are inevitable, so the drop in volumes last year is not surprising. With new, exciting models and battery production on the horizon, the potential for growth is clear. Securing this future, however, requires industrial and trade strategies that deliver the competitive conditions essential for growth amidst an increasingly protectionist global environment.”

The latest independent production outlook expects UK car and light van production to be around 839,000 units in 2025 before rising to 930,000 units in 2027, with the potential to get above one million units in 2028, and over 1.1 million by 2030.2 This is, however, dependent on global car and van market demand improving, positive economic conditions and greater consumer confidence, and the delivery of the competitive conditions necessary to ensure zero emission model launches stay on track.

Realising this ambition and unlocking future growth will require an industrial strategy with advanced automotive manufacturing at its heart, enabling innovation, attracting investment and supporting the country’s highly skilled workforce. Equally important is a healthy domestic market, given manufacturers build close to where they sell, as well as strong overseas demand, notably for electrified vehicles which the sector, and government, has committed billions to making.

The industry, therefore, needs market regulation that reflects the reality of natural demand and a fiscal framework that incentivises consumers to buy these new vehicles that are fundamental to the achievement of our shared net zero ambitions. This must be aligned with an ambitious trade strategy that maintains a tariff-free enhanced trade partnership with the EU, and balanced, commercially meaningful trade agreements and critical minerals agreements with existing and new trading partners.

The right strategies will help secure the sector’s position as a £100 billion global trade hub, with the potential to deliver £50 billion in UK growth over the coming decade, supporting government’s economic, societal and environmental ambitions.3

Notes to editors

1:  SMMT calculations based on publicly announced investment commitments, public and private, in UK automotive production and R&D in 2024.
2:  Based on independent production outlook produced by AutoAnalysis in November – cars and light vans only.
3: SMMT Trade Snapshot 2024 and SMMT Vision 2035.

About SMMT and the UK automotive industry

The Society of Motor Manufacturers and Traders (SMMT) is one of the largest and most influential trade associations, representing the automotive industry in the UK. The automotive industry is a vital part of the UK economy, integral to growth, the delivery of net zero and the UK as a global trade hub. It contributes £93 billion turnover and £22 billion value added to the UK economy, and invests around £4 billion each year in R&D. With 198,000 people employed directly in manufacturing and some 813,000 across the wider automotive industry. 

The UK manufactures almost every type of vehicle, from cars, to vans, taxis, trucks, buses and coaches, as well as specialist and off-highway vehicles, supported by more than 2,500 component providers and some of the world’s most skilled engineers. In addition, the sector has vibrant aftermarket and remanufacturing industries. The automotive industry also supports jobs in other key sectors – including advertising, chemicals, finance, logistics and steel.

SMMT’s Motor Industry Facts publication www.smmt.co.uk/reports/smmt-motor-industry-facts/

UK VEHICLE MANUFACTURING (data for December and FY 2024)

Hi-res charts available via Dropbox: https://www.dropbox.com/scl/fo/a1iat513l4t5r3rkdb57o/AJw7kC6rKE9DvMm6-E_Amlo?rlkey=cy9q0ydz6sbov67itj36ki4v0&st=adloem9m&dl=0 

 

SELLING BITCOIN MADE SIMPLE: LOCALCOIN’S NEW SELL ATM LAUNCHES IN AUSTRALIA!

MELBOURNE, Australia, Jan. 30, 2025 /PRNewswire/ — Australians can now sell their Bitcoin for cash instantly at select Localcoin Bitcoin ATMs, making it easier than ever to access their funds. As the country’s fastest-growing Bitcoin ATM provider, Localcoin is committed to enhancing the way users interact with cryptocurrency.

Buy and Sell Bitcoin instantly at Localcoin Bitcoin ATMs.
Buy and Sell Bitcoin instantly at Localcoin Bitcoin ATMs.

With cryptocurrency adoption surging and Bitcoin’s value steadily increasing, more Australians are seeking fast and secure ways to convert their digital assets into cash. To meet this growing demand, Localcoin now offers a seamless solution to convert Bitcoin into cash almost instantly at select ATMS.

“We’re thrilled to launch this feature for Australians,” said Jay Pandher, President of Localcoin. “Our goal is to simplify the crypto experience, making it accessible and approachable. Imagine selling your Bitcoin and receiving cash right in your hands with just a few taps. This is a huge step in our mission to support Australians in their digital currency journey.”

How It Works

Localcoin’s sell option is currently available at select locations across Australia, with plans to expand further in the near future. Users have two convenient ways to cash out their crypto:

  1. Visit a Localcoin Sell ATM : Convert Bitcoin to cash almost instantly at the ATM in just a few simple steps. 
  2. Pre-Sell Online : Save time by pre-selling your Bitcoin online before visiting the ATM. Once confirmed, you can withdraw cash instantly at the ATM. Learn more here.

Key Benefits of Localcoin Sell ATMs

  • No Lengthy Registration : Get started quickly with just ID verification and your phone number—no time-consuming processes required.
  • User-Friendly Experience : Designed for both beginners and experienced users with an intuitive, easy-to-use interface.
  • Secure Transactions : Localcoin employs stringent security measures to ensure safe and reliable transactions.
  • Compatible with Most Wallets : Sell your Bitcoin no matter where it’s stored—Localcoin ATMs accept most wallets for maximum convenience.

Expanding Across Australia

To date, Localcoin has installed nine Bitcoin ATMs that allow users to sell Bitcoin for cash. Looking ahead, the company plans to expand its reach by adding over 70 sell locations nationwide. Localcoin remains dedicated to making crypto transactions accessible to all Australians, further solidifying its position as a leader in the Bitcoin ATM industry.

CLICK HERE TO VIEW LOCALCOIN SELL ATMs

About Localcoin

Founded in 2017, Localcoin has cemented its position as Canada’s largest Bitcoin ATM provider and the fastest-growing provider in Australia. With a focus on simplicity, security, and speed, Localcoin’s mission is to make cryptocurrency accessible to everyone, whether they are new crypto users or experienced investors. For more information and to find a Localcoin ATM near you, visit https://localcoinatm.com/en-au/.

Media Contact: For media inquiries, please contact Naveed Ahmed, naveed.a@localcoinatm.com 

Photo – https://laotiantimes.com/wp-content/uploads/2025/01/localcoin_selling_bitcoin_made_simple__localcoin_s_new_sell_atm-1.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2025/01/localcoin_selling_bitcoin_made_simple__localcoin_s_new_sell_atm.jpg

Enfinity Global Expands U.S. Portfolio with 425 MW of Battery Energy Storage in Texas, Construction Planned to Start in 2025

MIAMI, Jan. 30, 2025 /PRNewswire/ — Enfinity Global Inc., a leader in renewable energy, today announced the expansion of its battery energy storage systems (BESS) portfolio with two new projects in Texas, with a total power capacity of 425 MW. The projects are expected to start construction in the second and fourth quarters of 2025. These additions bring Enfinity’s BESS pipeline in the U.S. to 6.6 GW, underscoring the company’s dedication to deploying innovative energy solutions to meet the growing load demands in key markets and segments such as AI and manufacturing. Enfinity Global is expected to invest over $7 Billion and create over 5,000 construction jobs in this sector alone in the next few years.

The projects, with a combined storage capacity of 850 MWh and a two-hour duration, are strategically located in ERCOT’s Houston and Dallas zones. ERCOT is experiencing unprecedented load growth, increasing the need for more renewables paired with BESS. Once operational, these projects are expected to help stabilize the ERCOT grid and support renewable energy expansion to meet Texas’ rising electricity demand, largely driven by new AI-driven data centers.

Carlos Domenech, CEO of Enfinity Global, commented, “We are proud to invest, power, and enable technology at an unprecedented speed, cost, and functionality in the race for global competitiveness. All while creating new jobs and making substantial investments in the United States economy.”

Enfinity Global is a rapidly expanding U.S.-based IPP. Its current portfolio in the U.S. includes 400 MW in operational assets, 19 GW of solar PV and energy storage under development, plus an additional 37 GW in negotiation. The company expects to have over 1 GW of solar and storage assets operational and under construction in the country this year.

Ricardo Díaz, CEO of Enfinity Global Americas, stated, “Enfinity’s proven capabilities with in-house greenfield development has allowed us to expand into executing stand-alone BESS projects. This positions us to play a key role in strengthening and balancing ERCOT power grids and create value-accretive investment opportunities for Enfinity and our financial partners.”

About Enfinity

Enfinity Global is a leading U.S.-based renewable energy and sustainability services company established in 2019. The company owns 32.1 GW portfolio of renewable energy and storage projects, including operational, under-construction, and development assets, with an additional 37 GW under negotiation across U.S.

 

ASSEMBLY UNVEILS STAGE AI

The industry’s most real, connected, and future-ready OS just got smarter, faster, and sharper

NEW YORK, Jan. 30, 2025 /PRNewswire/ — Assembly, a Stagwell (NASDAQ: STGW) agency, is proud to announce the launch of STAGE AI, the latest evolution of its proprietary operating system, STAGE. Now powered by artificial intelligence, STAGE AI represents a bold step forward in Assembly’s commitment to innovation—providing clients with technology that offers efficiency at scale while prioritizing incrementality to drive measurable business impact and outcomes. STAGE AI works centrally on all STAGE data sources to deliver insights with unmatched speed, precision, and scale. It also empowers teams to work smarter, transforming tasks that once took significant time into streamlined processes, end-to-end, that yield sharper results.

Purpose-built for the future, STAGE AI is distinct as it seamlessly integrates AI at the core of its OS, rather than simply serving as an add-on.

Tim Lippa, Global Chief Product Officer at Assembly adds, “Our perspective on AI goes beyond efficiency. It’s about using this transformative technology to deliver outcomes that directly impact our clients’ growth. With Stage AI, we’ve upgraded our STAGE Operating System to ensure AI isn’t just an enhancement—it’s the foundation.”

STAGE AI gives clients a competitive edge by proactively identifying opportunities for brand performance at scale. For example, AI-powered ‘Brand Monitor’ provides real-time insights into upper funnel brand performance, enabling quicker, smarter media allocation decisions. In the digital commerce space, STAGE AI enables proactive optimization of the customer journey, improves experiences and drives conversion rates for optimal business results. The measurable impact is clear: STAGE AI has already delivered a 30% improvement in campaign relevance for targeted audiences, and its ability to process data at record speeds ensures clients stay ahead of the curve.

“STAGE AI is not just an upgrade; it’s a transformation,” said Rick Acampora, Global CEO of Assembly. “This is the most real, connected, and future-ready technology in the industry, and now it’s even better. With AI seamlessly integrated into STAGE, we’ve created a smarter, faster, and more automated platform that allows our teams to deliver exceptional value to our clients, not just today, but for the future.”

With STAGE AI, Assembly continues to lead the way in marketing and commerce technology, proving that innovation is not about following trends but setting the standard. This new evolution underscores Assembly’s commitment to empowering teams and clients with technology that delivers smarter, faster, and more meaningful results.

For more information on STAGE AI, visit stageai.assemblyglobal.com

ABOUT STAGE AI
STAGE is Assembly’s customizable, global operating system designed to complement clients’ existing tech stack, address unique data & measurement challenges, and identify & implement real-time optimizations to boost brand performance. STAGE unifies, standardizes and democratizes data at scale globally. STAGE supports any data source, with 400+ sources of media and business data currently automated. Evolved over the last 15 years, STAGE continues to help clients realize the power of their data at scale and fuels finding opportunities to deliver growth. STAGE powers over twenty customizable applications that identify growth opportunities, deliver media efficiency and provide brand performance measurement for our clients.

ABOUT ASSEMBLY
Assembly is a leading global omnichannel media agency that merges data, talent, and technology to catalyze growth for the world’s most esteemed brands. Our holistic approach weaves together compelling brand narratives with a comprehensive suite of global media capabilities, driving performance and fostering significant business expansion. Our initiatives are powered by STAGE, our proprietary operating system, and executed by a dedicated global team of over 2,300 professionals across 35 offices worldwide. Committed to purposeful action, Assembly leads the way in social and environmental impact within the agency realm. As a proud member of Stagwell, the challenger network designed to revolutionize marketing, Assembly continues to set new standards of excellence. For more information, please visit assemblyglobal.com.

Contact
Mariana Delacqua
Mariana.delacqua@assemblyglobal.com

Assembly STAGE AI
Assembly STAGE AI

 

MakeMoneyOnline Launches New Gaming Platform: Earn Rewards by Playing Game

TOKYO, Jan. 30, 2025 /PRNewswire/ — Mint Town Co., Ltd. is pleased to announce the launch of its highly anticipated platform, MakeMoneyOnline, in January 2025.

This innovative platform redefines the online gaming experience by providing users with a fun and engaging way to earn rewards. Leveraging advanced AI and real-time analytics, MakeMoneyOnline empowers users to maximize their gaming efficiency and enjoyment, setting a new standard as the leading platform in the industry.

With a focus on delivering user satisfaction and a seamless experience, MakeMoneyOnline combines cutting-edge technology with entertainment, setting a new industry standard.

MakeMoneyOnline.cash
MakeMoneyOnline.cash

Key Features of MakeMoneyOnline:

  • Fun and Rewarding Games:
    • Users can enjoy a variety of exciting games that reward their progress and achievements with points, offering a streamlined and efficient way to maximize their time.
  • Enhanced Efficiency:
    • Compared to other platforms, MakeMoneyOnline provides users with a more optimized and time-saving way to earn points
  • AI-Powered Personalization:
    • The platform delivers personalized game recommendations tailored to user preferences, enabling players to focus on the games they enjoy most while maximizing their rewards.
  • Flexible Reward Options:
    • Earned points can be redeemed for a wide range of rewards, including gift cards and other exciting perks, offering users flexibility and convenience.
  • Seamless User Experience:
    • Designed with user-friendliness in mind, the platform provides a smooth and intuitive gaming and rewards experience.

“MakeMoneyOnline has been developed as the ultimate gaming platform where users can enjoy playing and earn rewards at the same time,” said Hironao Kunimitsu, CEO of Mint Town Co., Ltd. “The platform empowers individuals worldwide by offering a smarter, faster, and more enjoyable way to engage with gaming while earning meaningful rewards.”

Initially launching in the United States, MakeMoneyOnline is committed to global expansion, aiming to provide users worldwide with access to profitable and enjoyable gaming experiences, solidifying its position as a leader in the industry.

For more information, visit the official website: makemoneyonline.cash.

About Mint Town Co., Ltd.

Mint Town Co., Ltd. is a leading innovator in online earning solutions, dedicated to empowering users with cutting-edge platforms that make earning money simple and efficient. The company’s flagship platform, MakeMoneyOnline, integrates advanced AI, data-driven insights, and intuitive design to deliver the industry’s most profitable Get Paid To service.

Website: https://makemoneyonline.cash , https://minttown.jp/

AV-Comparatives Releases 2024 Summary Report: Celebrating Excellence in Cybersecurity

INNSBRUCK, Austria, Jan. 30, 2025 /PRNewswire/ — AV-Comparatives, the independent antivirus testing lab, is pleased to announce the publication of its annual Summary Report for 2024. This comprehensive report evaluates 16 leading consumer security products for Windows, assessing their performance across multiple rigorous tests conducted throughout the year.

AV-Comparatives Consumer Cybersecurity Summary Report 2024
AV-Comparatives Consumer Cybersecurity Summary Report 2024

Access the full report here: Summary Report 2024

Tested Products

The 2024 evaluation encompassed the following security solutions:

  • Avast Free Antivirus
  • AVG Internet Security
  • Avira Free Antivirus
  • Bitdefender Total Security
  • ESET HOME Security Essential
  • F-Secure Internet Security
  • G DATA Total Security
  • Kaspersky Standard
  • McAfee Total Protection
  • Microsoft Defender
  • Norton Antivirus Plus
  • Panda Free Antivirus
  • Quick Heal Internet Security
  • Total Defense Essential Anti-Virus
  • TotalAV Antivirus Pro
  • Trend Micro Internet Security

Key Highlights

In 2024, AV-Comparatives conducted a series of comprehensive tests to assess each product’s ability to:

  • Protect against real-world internet threats.
  • Detect and recent malicious programs.
  • Defend against advanced targeted attacks.
  • Operate efficiently without compromising system performance.

Outstanding Performances

While all evaluated products met acceptable standards, several distinguished themselves with exceptional performance:

  • ESET HOME Security Essential: Awarded Product of the Year 2024, ESET achieved the highest “Advanced+” rating in all seven tests, underscoring its superior protection capabilities.
  • Avast Free Antivirus: Recognized as a Top-Rated Product, Avast earned “Advanced+” in six out of seven tests and “Advanced” in one, securing the Gold Award in the Real-World Protection Test.
  • AVG Internet Security: Also a Top-Rated Product, AVG mirrored Avast’s achievements with “Advanced+” in six tests and “Advanced” in one, sharing the Gold Award in the Real-World Protection Test.
  • Bitdefender Total Security: As a Top-Rated Product, Bitdefender garnered “Advanced+” in six tests and “Advanced” in one, earning the Gold Award in the Malware Protection Test.
  • Kaspersky Standard: Honored as a Top-Rated Product, Kaspersky achieved “Advanced+” in six tests and “Advanced” in one, receiving the Gold Award in the False-Positives Test.

Additional Recognitions

The following products also demonstrated very commendable performance:

  • Avira Free Antivirus: Secured the Gold Award in the Real-World Protection Test, highlighting its robust defense against internet-borne threats.
  • McAfee Total Protection: Earned the Gold Award in the Performance Test, reflecting minimal impact on system performance.
  • G DATA Total Security: Received the Silver Award in the Malware Protection Test, showcasing effective malware detection capabilities.

Areas for Improvement

While the majority of products excelled, Trend Micro Internet Security and Quick Heal Internet Security exhibited areas needing enhancement to align with industry leaders. AV-Comparatives encourages these vendors to analyse the detailed findings to bolster their products’ effectiveness in future evaluations.

Comprehensive User-Interface Review

The Summary Report also includes an in-depth user-interface review of all tested products, providing insights into usability aspects such as installation processes, security alerts, scan options, quarantine management, and access controls.

Cybersecurity and Endpoint Protection for Enterprises and Corporate Users

The latest test results for leading business security solutions, including Avast, Bitdefender, Cisco, CrowdStrike, Elastic, ESET, G Data, K7, Kaspersky, Microsoft, NetSecurity, Rapid7, SenseOn, Sophos, Trellix, VIPRE, and VMware, are now available on AV-Comparatives’ website.

Commitment to Transparency and Excellence

AV-Comparatives remains dedicated to delivering transparent, comprehensive, and scientifically rigorous cybersecurity assessments. By providing unbiased evaluations, we aim to empower consumers and businesses to make informed decisions about their digital security solutions.

For a detailed analysis and the full 2024 Summary Report, please visit:

Access the full report here: Summary Report 2024

Media contact: media@av-comparatives.org, +43512287788